Rubius Therapeutics (RUBY) Issues Strategic Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- Needham Starts NeoVolta (NEOV) at Buy
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Morgan Stanley on Rubius (RUBY) New Strategy and Restructuring: 'removes potential for near-term clinical catalyst'
September 13, 2022 9:48 AM EDTMorgan Stanley analyst Jeffrey Hung reiterated an Equalweight rating and $1.50 price target on Rubius (NASDAQ: RUBY).
The analyst comments "Our Take: Update removes potential for near-term clinical catalysts. We acknowledge the potential advantages of the next-gen platform and understand streamlining the... More
